Europe Blood Collection Tubes for Liquid Biopsy Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (ccfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, Intracellular RNA Tubes, and Others), Material (Glass and Plastic), Application (

Europe Blood Collection Tubes for Liquid Biopsy Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (ccfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, Intracellular RNA Tubes, and Others), Material (Glass and Plastic), Application (In-Vitro Diagnostics (IVD) and Research), and End User (Genetic Diagnostic Labs, R&D Centres, Conventional Diagnostic Centres, and Others)

The Europe blood collection tubes for liquid biopsy market is expected to reach US$ 73.65 thousand by 2028 from US$ 23.15 thousand in 2021; it is estimated to grow at a CAGR of 18.0% from 2021-2028. The growth of the market is due to the increasing prevalence of cancer worldwide and rising demand for minimally invasive diagnostic tests. However, lack of skilled professionals leading to inaccurate blood collection tubes for liquid biopsy analysis is expected to restrict the market growth during the forecast period.

There is a growing preference for minimally or non-invasive tests among patients for diagnostic purposes. Early cancer detection, mutation detection, tumor monitoring throughout treatment, and recurrence monitoring are possible using liquid biopsy, which uses a non-invasive blood sample. Researchers can trace all epigenetic and genetic changes in solid tumors using blood samples with the help of liquid biopsy, which is a simple and non-invasive technique. Patients are at a lesser risk with liquid biopsies, and clinicians can readily conduct them multiple times. Patients prefer minimally invasive procedures because the advanced instruments used in such procedures allow for more delicate and complex work to be performed with lower risk, less pain, and less scarring.

Due to technological advancements in feasibility and processing times, liquid biopsy has recently attracted considerable interest as a non-invasive alternative to tissue biopsy in cancer patients. Liquid biopsy adoption is aided by an increased understanding of improved minimally invasive cancer detection technologies. The market's growth is influenced by the rising demand for non-invasive tools and laboratory acceptance of liquid biopsy. A blood test is painless, non-invasive, has no risks, and cuts down the cost and time it takes to diagnose a problem. CTCs, cfDNAs, exosomes, and microvesicles can be detected in a blood sample, making blood-based liquid biopsies more popular. A liquid biopsy is a non-invasive and simple alternative to surgical biopsies that allows doctors to discover a range of information about tumors from a simple blood sample. A surgical biopsy is a highly invasive procedure, and surgeons avoid putting the patient at risk and are extremely costly. Hence, the market revenue is driven by safe and non-invasive cancer diagnostic techniques. Further, rising technological advancements in blood collection tubes for liquid biopsy are propelling the market growth.

The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Spain, Italy, Germany, France, and the UK are among the most affected European countries and witnessed a high number of deaths. WorkfAccording to the international health regulation, the COVID-19 outbreak had been declared by World Health Organization as a public health emergency of international concern. The COVID-19 emergency had undoubtedly aided in encouraging the general population to try out and expand their usage of digital services, particularly to avoid having to visit a health center in person. However, there are still several constraints that hinder these services from becoming more widely adopted.

The unprecedented impact of COVID-19 has been far-reaching, but the effects on cancer patients make them one of the worst affected groups. COVID-19 pandemic had profoundly impacted the number of patients undergoing cancer screening, diagnosis, and treatment. The increased pressure due to the growing rate of COVID-19 patients' hospitalization led to the re-profiling of many hospitals and departments, including oncology clinics for treating patients with the COVID-19. Consequently, according to one study, many diagnostic and treatment procedures had been canceled or postponed worldwide, including 2.3 million cancer surgeries. Thus, the COVID-19 pandemic had a negative impact on Europe blood collection tubes for liquid biopsy market.

The Europe blood collection tubes for liquid biopsy market, based on product, has been classified into ccfDNA tubes, cfRNA tubes, CTC tubes, gDNA tubes, intracellular RNA tubes, and others. The ccfDNA segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR during the forecast period.

The Europe blood collection tubes for liquid biopsy market, based on material, is segmented into glass and plastic. In 2021, the plastic segment held a larger share of the market. However, the glass segment is expected to witness growth in demand at a faster CAGR from 2021 to 2028, owing to the rise in the detection and diagnosis of various medical conditions globally.

The Europe blood collection tubes for liquid biopsy market, based on application, is segmented into In-vitro diagnostics (ivd), and research. In 2021, the In-Vitro diagnostics segment is likely to hold a larger share of the market. Moreover, the segment is expected to witness growth in demand at a faster CAGR from 2021 to 2028, owing to the rise in the detection and diagnosis of various medical conditions globally.

A few of the primary and secondary sources referred to while preparing the report on the Europe blood collection tubes for liquid biopsy market are German Cancer Society (Deutsche Krebsgesellschaft), Association of German Inflammatory Centres, and Agency for Research on Cancer (IARC).

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe blood collection tubes for liquid biopsy market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Europe blood collection tubes for liquid biopsy market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.